Arrowhead presents plozasiran data showing major reductions in pancreatitis and lipid levels
Arrowhead Pharmaceuticals reported that plozasiran cut acute pancreatitis event rates by 78% across a pooled analysis of 757 severe hypertriglyceridemia patients and by 91% in those with a recent pancreatitis episode. The same drug also produced mean LDL‑C reductions of up to 65% and median triglyceride reductions of up to 78% in early dose‑escalation studies. The findings were presented at the American Heart Association Scientific Sessions 2026 and were not placebo‑adjusted.
Why it matters
Arrowhead says the results bolster its cardiometabolic pipeline and could accelerate development of plozasiran toward regulatory approval. Investors may view the data as a catalyst for future revenue growth if the drug advances successfully.
Key facts
- 1The pooled analysis randomized 757 adults with severe hypertriglyceridemia to plozasiran 25 mg or placebo every three months. stocktitan.net
- 2Plozasiran reduced the rate of all adjudicated acute pancreatitis events by 78% overall. stocktitan.net
- 3In patients with a recent pancreatitis history, the reduction was 91% versus placebo. stocktitan.net
- 4Single doses of ARO‑DIMER‑PA produced mean LDL‑C reductions from baseline of up to 65%. stocktitan.net
- 5Median triglyceride reductions from baseline reached up to 78% in the same studies. stocktitan.net
- 6Treatment‑emergent adverse events occurred in all 21 plozasiran‑treated participants and in nine of ten placebo participants; most were Grade 1 or Grade 2. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.